Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

Jun 04, 2018

SELL
$16.06 - $25.35 $1.31 Million - $2.07 Million
-81,683 Closed
0 $0
Q4 2017

Jun 04, 2018

BUY
$10.51 - $17.22 $858,488 - $1.41 Million
81,683
81,683 $1.37 Million

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $13.1M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Eam Global Investors LLC Portfolio

Follow Eam Global Investors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Global Investors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Global Investors LLC with notifications on news.